Human lymphoblastoid interferon treatment for patients with hepatitis C virus-related cirrhosis

Norihiro Furusyo, Jun Hayashi, Kumiko Ueno, Yasunori Sawayama, Yasunobu Kawakami, Yasuhiro Kishihara, Seizaburo Kashiwagi

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

To evaluate the efficacy and safety of human lymphoblastoid interferon treatment (interferon alfa) for patients with compensated cirrhosis caused by hepatitis C virus (HCV) infection, we randomly assigned 82 cirrhotic patients with chronic HCV infection (44 men, 38 women; mean age, 58.6 years) to two groups: 41 patients were treated with interferon alfa (480 million U over 6 months), and the other patients received no drug treatment. HCV RNA genotypes were determined by polymerase chain reaction (PCR) testing using type- specific primers. HCV RNA levels were measured by competitive PCR testing. No untreated patients eliminated HCV RNA from the serum or had a decrease in the level of alanine aminotransferase to normal during the observation period. Of the 34 patients who completed interferon alfa treatment, 6 (17.6%) who were considered complete responders eliminated HCV RNA from the serum by the end of treatment and sustained this elimination throughout a 6-month follow-up period. Complete responders constituted 6 (46.2%) of 13 patients with HCV RNA levels ≤105 copies/50 μL, but none of the 21 patients with levels >105 copies/50 μL were complete responders. Two (7.1%) of 28 patients with genotype 1b infection and 4 (66.7%) of 6 with genotype 2a were complete responders. Five patients withdrew because of interferon alfa-induced side effects (1 for thrombocytopenia, 3 for severe general malaise, and 1 for impotence), and 2 withdrew after being diagnosed with hepatocellular carcinoma. Hepatic failure did not occur in any treated patient in the present study. These findings indicate that interferon alfa treatment is useful for compensated cirrhosis caused by HCV infection if the HCV RNA levels are low and the infection is of genotype 2a.

Original languageEnglish
Pages (from-to)1352-1367
Number of pages16
JournalClinical Therapeutics
Volume19
Issue number6
DOIs
Publication statusPublished - Jan 1 1997

Fingerprint

Interferon-alpha
Hepacivirus
Fibrosis
RNA
Virus Diseases
Genotype
Therapeutics
Polymerase Chain Reaction
Liver Failure
Erectile Dysfunction
Chronic Hepatitis C
Infection
Serum
Alanine Transaminase
Hepatocellular Carcinoma
Observation
Safety

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Furusyo, N., Hayashi, J., Ueno, K., Sawayama, Y., Kawakami, Y., Kishihara, Y., & Kashiwagi, S. (1997). Human lymphoblastoid interferon treatment for patients with hepatitis C virus-related cirrhosis. Clinical Therapeutics, 19(6), 1352-1367. https://doi.org/10.1016/S0149-2918(97)80010-0

Human lymphoblastoid interferon treatment for patients with hepatitis C virus-related cirrhosis. / Furusyo, Norihiro; Hayashi, Jun; Ueno, Kumiko; Sawayama, Yasunori; Kawakami, Yasunobu; Kishihara, Yasuhiro; Kashiwagi, Seizaburo.

In: Clinical Therapeutics, Vol. 19, No. 6, 01.01.1997, p. 1352-1367.

Research output: Contribution to journalArticle

Furusyo, N, Hayashi, J, Ueno, K, Sawayama, Y, Kawakami, Y, Kishihara, Y & Kashiwagi, S 1997, 'Human lymphoblastoid interferon treatment for patients with hepatitis C virus-related cirrhosis', Clinical Therapeutics, vol. 19, no. 6, pp. 1352-1367. https://doi.org/10.1016/S0149-2918(97)80010-0
Furusyo, Norihiro ; Hayashi, Jun ; Ueno, Kumiko ; Sawayama, Yasunori ; Kawakami, Yasunobu ; Kishihara, Yasuhiro ; Kashiwagi, Seizaburo. / Human lymphoblastoid interferon treatment for patients with hepatitis C virus-related cirrhosis. In: Clinical Therapeutics. 1997 ; Vol. 19, No. 6. pp. 1352-1367.
@article{6a4ea620cb154d59b246524847ddd334,
title = "Human lymphoblastoid interferon treatment for patients with hepatitis C virus-related cirrhosis",
abstract = "To evaluate the efficacy and safety of human lymphoblastoid interferon treatment (interferon alfa) for patients with compensated cirrhosis caused by hepatitis C virus (HCV) infection, we randomly assigned 82 cirrhotic patients with chronic HCV infection (44 men, 38 women; mean age, 58.6 years) to two groups: 41 patients were treated with interferon alfa (480 million U over 6 months), and the other patients received no drug treatment. HCV RNA genotypes were determined by polymerase chain reaction (PCR) testing using type- specific primers. HCV RNA levels were measured by competitive PCR testing. No untreated patients eliminated HCV RNA from the serum or had a decrease in the level of alanine aminotransferase to normal during the observation period. Of the 34 patients who completed interferon alfa treatment, 6 (17.6{\%}) who were considered complete responders eliminated HCV RNA from the serum by the end of treatment and sustained this elimination throughout a 6-month follow-up period. Complete responders constituted 6 (46.2{\%}) of 13 patients with HCV RNA levels ≤105 copies/50 μL, but none of the 21 patients with levels >105 copies/50 μL were complete responders. Two (7.1{\%}) of 28 patients with genotype 1b infection and 4 (66.7{\%}) of 6 with genotype 2a were complete responders. Five patients withdrew because of interferon alfa-induced side effects (1 for thrombocytopenia, 3 for severe general malaise, and 1 for impotence), and 2 withdrew after being diagnosed with hepatocellular carcinoma. Hepatic failure did not occur in any treated patient in the present study. These findings indicate that interferon alfa treatment is useful for compensated cirrhosis caused by HCV infection if the HCV RNA levels are low and the infection is of genotype 2a.",
author = "Norihiro Furusyo and Jun Hayashi and Kumiko Ueno and Yasunori Sawayama and Yasunobu Kawakami and Yasuhiro Kishihara and Seizaburo Kashiwagi",
year = "1997",
month = "1",
day = "1",
doi = "10.1016/S0149-2918(97)80010-0",
language = "English",
volume = "19",
pages = "1352--1367",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "6",

}

TY - JOUR

T1 - Human lymphoblastoid interferon treatment for patients with hepatitis C virus-related cirrhosis

AU - Furusyo, Norihiro

AU - Hayashi, Jun

AU - Ueno, Kumiko

AU - Sawayama, Yasunori

AU - Kawakami, Yasunobu

AU - Kishihara, Yasuhiro

AU - Kashiwagi, Seizaburo

PY - 1997/1/1

Y1 - 1997/1/1

N2 - To evaluate the efficacy and safety of human lymphoblastoid interferon treatment (interferon alfa) for patients with compensated cirrhosis caused by hepatitis C virus (HCV) infection, we randomly assigned 82 cirrhotic patients with chronic HCV infection (44 men, 38 women; mean age, 58.6 years) to two groups: 41 patients were treated with interferon alfa (480 million U over 6 months), and the other patients received no drug treatment. HCV RNA genotypes were determined by polymerase chain reaction (PCR) testing using type- specific primers. HCV RNA levels were measured by competitive PCR testing. No untreated patients eliminated HCV RNA from the serum or had a decrease in the level of alanine aminotransferase to normal during the observation period. Of the 34 patients who completed interferon alfa treatment, 6 (17.6%) who were considered complete responders eliminated HCV RNA from the serum by the end of treatment and sustained this elimination throughout a 6-month follow-up period. Complete responders constituted 6 (46.2%) of 13 patients with HCV RNA levels ≤105 copies/50 μL, but none of the 21 patients with levels >105 copies/50 μL were complete responders. Two (7.1%) of 28 patients with genotype 1b infection and 4 (66.7%) of 6 with genotype 2a were complete responders. Five patients withdrew because of interferon alfa-induced side effects (1 for thrombocytopenia, 3 for severe general malaise, and 1 for impotence), and 2 withdrew after being diagnosed with hepatocellular carcinoma. Hepatic failure did not occur in any treated patient in the present study. These findings indicate that interferon alfa treatment is useful for compensated cirrhosis caused by HCV infection if the HCV RNA levels are low and the infection is of genotype 2a.

AB - To evaluate the efficacy and safety of human lymphoblastoid interferon treatment (interferon alfa) for patients with compensated cirrhosis caused by hepatitis C virus (HCV) infection, we randomly assigned 82 cirrhotic patients with chronic HCV infection (44 men, 38 women; mean age, 58.6 years) to two groups: 41 patients were treated with interferon alfa (480 million U over 6 months), and the other patients received no drug treatment. HCV RNA genotypes were determined by polymerase chain reaction (PCR) testing using type- specific primers. HCV RNA levels were measured by competitive PCR testing. No untreated patients eliminated HCV RNA from the serum or had a decrease in the level of alanine aminotransferase to normal during the observation period. Of the 34 patients who completed interferon alfa treatment, 6 (17.6%) who were considered complete responders eliminated HCV RNA from the serum by the end of treatment and sustained this elimination throughout a 6-month follow-up period. Complete responders constituted 6 (46.2%) of 13 patients with HCV RNA levels ≤105 copies/50 μL, but none of the 21 patients with levels >105 copies/50 μL were complete responders. Two (7.1%) of 28 patients with genotype 1b infection and 4 (66.7%) of 6 with genotype 2a were complete responders. Five patients withdrew because of interferon alfa-induced side effects (1 for thrombocytopenia, 3 for severe general malaise, and 1 for impotence), and 2 withdrew after being diagnosed with hepatocellular carcinoma. Hepatic failure did not occur in any treated patient in the present study. These findings indicate that interferon alfa treatment is useful for compensated cirrhosis caused by HCV infection if the HCV RNA levels are low and the infection is of genotype 2a.

UR - http://www.scopus.com/inward/record.url?scp=0031409685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031409685&partnerID=8YFLogxK

U2 - 10.1016/S0149-2918(97)80010-0

DO - 10.1016/S0149-2918(97)80010-0

M3 - Article

C2 - 9444445

AN - SCOPUS:0031409685

VL - 19

SP - 1352

EP - 1367

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 6

ER -